Novo Nordisk Flags Cagriloutide promised in the following obesity medication hunting

Novo Nordisk Wednesday, promising promising test results at an advanced stage for its new treatment of Cagrilinitides, because the Danish pharmaceutical giant is looking for a new generation alternative to its Wegovy Wegovy weight loss medication.

Early analysis of a Redefine 1 trial of phase 3 has shown that the injection of Cagriloutide monotherapy once a week helped patients reduce their weight by 11.8% on average after 68 weeks, compared to 2.3% for people on site, said the company.

Cagrontintide is an emerging form of weight loss treatment that differs existing GLP-1s, such as Wegovy de Novo Nordisk and Zepbound from Eli Lilly. The analog of Amyline with prolonged action that works by imitating a hormone co-skid with insulin in the pancreas to increase satiety.

The drug manufacturer has also underlined the increased tolerability profile of treatment, describing it as “well tolerated”, the most common side effects being gastrointestinal and mainly “light to moderate”.

Novo Nordisk’s shares increased 1.3% to 11:15 a.m. London time, shortly after the results are released.

“In our clinical trials, Cagrontintide has provided substantial weight loss, in a distinct manner compared to approved obesity drugs, and seems to be well tolerated,” Martin Holst Lange, scientific director of Novo Nordisk and executive vice-president of research and development in a statement.

“We are delighted that this data, the first phase 3 data of new generation Amylin therapy, is promising and we are impatient to study more before the potential of Cagrintide in the dedicated phase 3 renewal program,” added Lange.

Novo Nordisk is looking for a new generation obesity treatment after the successful success of its ozempic diabetes and its Wegovy obesity treatments have recently undergone food constraints and increased competition from the manufacturers of copy -made drugs.

Medication manufacturers are also looking for alternative treatments for patients who find it difficult to remain GLP-1 in the long term. Roche and Zealand Pharma also develop treatment with analog obesity of the Amyline known as Petrelontide.

Investors were previously disappointed with the results of the tests at an advanced stage for Cagrisema, a combined therapy that combines semaglutide, the active ingredient of Wegovy, with Cagriloutide.

However, Soren Lontoft, analyst of pharmacy actions at Sydbank, told CNBC that the secondary profile was perhaps the most promising aspect of the new treatment.

“The profile of the side effect for Cagrontintide is more interesting than weight loss. A more favorable side effect profile (with a low stop rate) than Wegovy and Zepbound is what I am looking for,” said Lontoft by email on Tuesday.

The results of the sub-analysis test, which were presented to the European association for the study of diabetes Congress in Vienna, Austria, evaluated adult patients with obesity or overweight and comorbidity linked to weight without diabetes.

A dedicated phase 3 renewal test – which studies the effectiveness and safety of the drug in patients with obesity or overweight, but without associated comorbidities – should start at the end of 2025.